Cargando…
Feasibility Evaluation of Radioimmunoguided Surgery of Breast Cancer
Breast-conserving surgery involves completely excising the tumour while limiting the amount of normal tissue removed, which is technically challenging to achieve, especially given the limited intraoperative guidance available to the surgeon. This study evaluates the feasibility of radioimmunoguided...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3299315/ https://www.ncbi.nlm.nih.gov/pubmed/22518303 http://dx.doi.org/10.1155/2012/545034 |
_version_ | 1782226107015102464 |
---|---|
author | Ravi, Ananth Reilly, Raymond M. Holloway, Claire M. B. Caldwell, Curtis B. |
author_facet | Ravi, Ananth Reilly, Raymond M. Holloway, Claire M. B. Caldwell, Curtis B. |
author_sort | Ravi, Ananth |
collection | PubMed |
description | Breast-conserving surgery involves completely excising the tumour while limiting the amount of normal tissue removed, which is technically challenging to achieve, especially given the limited intraoperative guidance available to the surgeon. This study evaluates the feasibility of radioimmunoguided surgery (RIGS) to guide the detection and delineation of tumours intraoperatively. The 3D point-response function of a commercial gamma-ray-detecting probe (GDP) was determined as a function of radionuclide ((131)I, (111)In,( 99m)Tc), energy-window threshold, and collimator length (0.0–3.0-cm). This function was used to calculate the minimum detectable tumour volumes (MDTVs) and the minimum tumour-to-background activity concentration ratio (T:B) for effective delineation of a breast tumour model. The GDP had larger MDTVs and a higher minimum required T:B for tumour delineation with (131)I than with (111)In or (99m)Tc. It was shown that for (111)In there was a benefit to using a collimator length of 0.5-cm. For the model used, the minimum required T:B required for effective tumour delineation was 5.2 ± 0.4. RIGS has the potential to significantly improve the accuracy of breast-conserving surgery; however, before these benefits can be realized, novel radiopharmaceuticals need to be developed that have a higher specificity for cancerous tissue in vivo than what is currently available. |
format | Online Article Text |
id | pubmed-3299315 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-32993152012-04-19 Feasibility Evaluation of Radioimmunoguided Surgery of Breast Cancer Ravi, Ananth Reilly, Raymond M. Holloway, Claire M. B. Caldwell, Curtis B. Int J Mol Imaging Research Article Breast-conserving surgery involves completely excising the tumour while limiting the amount of normal tissue removed, which is technically challenging to achieve, especially given the limited intraoperative guidance available to the surgeon. This study evaluates the feasibility of radioimmunoguided surgery (RIGS) to guide the detection and delineation of tumours intraoperatively. The 3D point-response function of a commercial gamma-ray-detecting probe (GDP) was determined as a function of radionuclide ((131)I, (111)In,( 99m)Tc), energy-window threshold, and collimator length (0.0–3.0-cm). This function was used to calculate the minimum detectable tumour volumes (MDTVs) and the minimum tumour-to-background activity concentration ratio (T:B) for effective delineation of a breast tumour model. The GDP had larger MDTVs and a higher minimum required T:B for tumour delineation with (131)I than with (111)In or (99m)Tc. It was shown that for (111)In there was a benefit to using a collimator length of 0.5-cm. For the model used, the minimum required T:B required for effective tumour delineation was 5.2 ± 0.4. RIGS has the potential to significantly improve the accuracy of breast-conserving surgery; however, before these benefits can be realized, novel radiopharmaceuticals need to be developed that have a higher specificity for cancerous tissue in vivo than what is currently available. Hindawi Publishing Corporation 2012 2012-02-20 /pmc/articles/PMC3299315/ /pubmed/22518303 http://dx.doi.org/10.1155/2012/545034 Text en Copyright © 2012 Ananth Ravi et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Ravi, Ananth Reilly, Raymond M. Holloway, Claire M. B. Caldwell, Curtis B. Feasibility Evaluation of Radioimmunoguided Surgery of Breast Cancer |
title | Feasibility Evaluation of Radioimmunoguided Surgery of Breast Cancer |
title_full | Feasibility Evaluation of Radioimmunoguided Surgery of Breast Cancer |
title_fullStr | Feasibility Evaluation of Radioimmunoguided Surgery of Breast Cancer |
title_full_unstemmed | Feasibility Evaluation of Radioimmunoguided Surgery of Breast Cancer |
title_short | Feasibility Evaluation of Radioimmunoguided Surgery of Breast Cancer |
title_sort | feasibility evaluation of radioimmunoguided surgery of breast cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3299315/ https://www.ncbi.nlm.nih.gov/pubmed/22518303 http://dx.doi.org/10.1155/2012/545034 |
work_keys_str_mv | AT raviananth feasibilityevaluationofradioimmunoguidedsurgeryofbreastcancer AT reillyraymondm feasibilityevaluationofradioimmunoguidedsurgeryofbreastcancer AT hollowayclairemb feasibilityevaluationofradioimmunoguidedsurgeryofbreastcancer AT caldwellcurtisb feasibilityevaluationofradioimmunoguidedsurgeryofbreastcancer |